Please login to the form below

Not currently logged in

WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines

The no-fault compensation fund will be accessible via a web portal by 31 March 2021

The World Health Organization (WHO) has signed an agreement on behalf of the international vaccines-sharing facility COVAX for a no-fault compensation programme for rare serious side effects associated with vaccines distributed via the scheme.

According to the WHO, the programme is the first vaccine injury compensation mechanism operating on an international scale. It covers all 92 low- and middle-income countries and economies that are eligible for support from the COVAX Facility until 30 June 2022.

The compensation programme will offer all eligible individuals a ‘fast, fair, robust and transparent’ process for gaining compensation in the rare event that they experience a serious side effect associated with a COVAX-distributed vaccine.

The COVAX programme will provide a no-fault lump sum compensation in full and final settlement of any claims, the WHO said in a statement.

This strategy aims to reduce the need for making use of law courts, which could potentially be a lengthy and costly process.

The no-fault compensation fund will be accessible via a web portal by 31 March 2021, although eligible individuals can apply for compensation under the programme even if they received a COVAX-distributed vaccine prior to this date.

The programme will initially be financed through Gavi COVAX Advance Market Commitment (AMC) funding.

“This no-fault compensation mechanism helps to ensure that people in AMC-eligible countries and economies can benefit from the cutting-edge science that has delivered COVID-19 vaccines in record time,” said Tedros Adhanom Ghebreyesus, director-general of the WHO.

The COVAX Facility – which is the vaccine pillar of the World Health Organization's (WHO) ACT Accelerator  –  is aiming to deliver at least two billion doses of safe and effective COVID-19 vaccines by the end of 2021 to all participating countries.

It is co-led by the WHO, Gavi and the Coalition for Epidemic Preparedness Innovations (CEPI), organisations that are working in partnership with vaccine manufacturers from developed and developing countries.

Last week, the European Commission announced that the EU will double its contribution to COVAX, with an additional pledge of €500m.

The additional €500m contribution is made up of a new €300m EU grant and €200m in guarantees by the European Fund for Sustainable Development plus (EFSD+).

The new funds double the EU’s previous €500m commitment to COVAX, consisting of a €100m grant and a €400m in guarantees from the EU budget.

Last week, the leaders of the G7 also pledged to increase their financial commitments to the ACT Accelerator and COVAX Facility with an extra $7.5bn.

Article by
Lucy Parsons

24th February 2021

From: Regulatory



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....
Looking back at the year when everything changed
COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families....